Kornimate/medical-research-clean huggingface dataset:
prone positioning in neurologically deceased potential organ donors to improve donor lung function and lung transplant recipient outcomes

Conditions: Lung Transplant Failure

Summary: the purpose of this study is to determine the practicality of performing a future, large-scale study. the future study will look at the effect of mechanical ventilation in neurologically deceased (brain-dead) lung donors who are positioned to lay flat on their stomach (prone position), compared to donors who are positioned to lay flat on their back (supine position). the study will also look at the potential impact of prone positioning of the donor on transplant recipients of the study organs. the investigators are doing this study because the investigators want to increase the availability of donor lungs for lung transplant. lung transplant is a life-saving treatment for individuals with lung disease, but there are not enough donated lungs to meet demand. researchers are looking for better ways of preventing donated lungs from becoming unsuitable for transplant. because of this, the goal of our study is to test whether prone positioning in neurologically deceased (brain-dead) lung donors can improve donor lung function and decrease complications, potentially increasing the number of donor lungs that can be used for transplant.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years 2. neurological determination of death at time of study entry 3. consent to organ donation 4. eligible for organ donation as confirmed by trillium gift of life network coordinator exclusion criteria: 1. open chest or abdominal wounds on the ventral body surface 2. absolute contraindication to lung transplantation on initial eligibility screening: * infection i. positive hiv, hbsag, human t-lymphotropic virus-i/ii test results ii. positive west nile virus (wnv pcr) test results iii. rabies diagnosis or within the last 6 months bitten by an animal proven to have rabies iv. active endocarditis v. active encephalitis or meningitis of unknown etiology vi. active disseminated tuberculosis vii. viral hemorrhagic fever including ebola or known exposure to person with ebola viii. covid-19 presumptive or confirmed positive in the last 14 days * malignancy i. donors with active cancer (donors receiving chemotherapy or radiation therapy or palliative cancer care within the last 5 years); excluding skin and primary brain tumors and prostate cancers. ii. donors with a history of the following malignancies: * lung cancer * choriocarcinoma * breast cancer * colon cancer within the last 10 years iii. donors with active or past history of melanoma o clinician decision that prone position is contraindicated
biological markers to identify early sepsis and acute lung injury

Conditions: Sepsis; Acute Lung Injury

Summary: there are no clear markers to identify sepsis and acute lung injury at early stage in clinical settings which would result in improved survival of the patients. in collaboration with the research team led by dr. zhang at st. michael's hospital, toronto, we have initiated a pilot study looking for biological markers to detect severe sepsis and ards. we have found that human neutrophils peptides (a-defensins), certain coagulation variables and cytokine levels are very sensitive markers to differentiate severe sepsis, ards from cardiovascular diseases in icu patients. these findings may provide valuable information for therapeutic guideline in clinical practice. the present study will focus on testing 'biological markers' to identify patients with sepsis and acute lung injury. we will examine the roles of three components of markers including inflammation, neutrophil activation and coagulation. we are hoping that this proposed translational research will help develop novel therapeutic strategy in sepsis and acute lung injury patients.


Eligibility criteria:
inclusion criteria: * meet diagnostic criteria of ≧2 sirs or acute lung injury. * get agreement of patient's attending physician and inform consent form patient or family. exclusion criteria: * use antibiotics over 24 hrs（only sirs group）. * active bleeding. * pregnancy. * active cancer (refer to malignancy which is recently diagnosed, under treatment, or relapsed) * vs or subject or family refuse

Keywords: biological markers sepsis acute lung injury
clinical study on the efficacy and safety of hetropapa ethanolamine tablets in the treatment of thrombocytopenia caused by concurrent radiotherapy and chemotherapy in cervical cancer

Conditions: Tumor Chemotherapy-related Thrombocytopenia

Summary: this study is a single arm, single center and exploratory clinical study, which aims to explore the efficacy and safety of hetropapa ethanolamine tablets in the treatment of thrombocytopenia caused by concurrent radiotherapy and chemotherapy of cervical cancer. the primary end point was the proportion of subjects who were effective after treatment with hetropapa in the first cycle after treatment, that is, the platelet value recovered to ≥ 100 x 109 / l after treatment. the main inclusion criteria were: voluntary participation in the trial and signing informed consent; age ≥ 18 years old, regardless of gender; cervical cancer was diagnosed by histopathology or cytology; platelet \< 75 × 109/l； at the time of screening, the expected survival time is ≥ 12 weeks, and can be treated with the current chemotherapy regimen for at least 1 cycle.


Eligibility criteria:
inclusion criteria: * voluntarily participate in the trial and sign the informed consent form; age ≥ 18 years old, regardless of gender; cervical cancer was diagnosed by histopathology or cytology; platelet \< 75 × 109/l at the time of screening, the expected survival time is ≥ 12 weeks, and can be treated with the current chemotherapy regimen for at least 1 cycle exclusion criteria: * screening or baseline platelet value \< 30 × 109/l suffering from the following hematopoietic system diseases other than thrombocytopenia (cit) caused by tumor chemotherapy drugs, including but not limited to leukemia, primary immune thrombocytopenia, bone marrow proliferative diseases, multiple myeloma and myelodysplastic syndrome; thrombocytopenia caused by causes other than cit occurred within 6 months before screening, including but not limited to chronic liver disease, hypersplenism, infection and bleeding; clinical manifestations of severe bleeding within 2 weeks before screening, such as gastrointestinal tract or central nervous system bleeding; neutrophil absolute value \< 1.0 × 109 / l, hemoglobin \< 80g / l; it is allowed to use granulocyte colony stimulating factor, erythrocyte and epo infusion in line with clinical routine; the researcher believes that participating in the trial has a great risk to the subject's health or safety, or other situations that may affect the efficacy evaluation.
a large-scale research for immunotherapy of glioblastoma with autologous heat shock protein gp96

Conditions: Glioma of Brain

Summary: this trial is to further study the safety and effectiveness of autologous gp96 treatment of glioblastoma on the basis of preliminary work.

rationale: heat shock protein gp96-peptide complex made from a person's tumor cells may help the body build an effective immune response to kill tumor cells. overall goals: - to evaluate the safety and induction of anti-tumor immunity by administration of an immunogenic human tumor cell vaccine, and assess immune response in relation to clinical outcome. primary aim: - to further evaluate effectiveness of autologous gp96 treatment of glioblastoma on the basis of preliminary work. secondary aims: to study the immune response to vaccination, to monitor clinical responses , to further the safety of vaccine.

Eligibility criteria:
inclusion criteria: 1. able to read and understand the informed consent document; must sign the informed consent; 2. aged 18 to 75 years old , sex is not limited; 3. newly diagnosed supratentoria glioma, must have undergone a at least a 80% resection; 4. availability of at least 4 g tumor sample; 5. patient must receive concurrent chemoradiotherapy (temozolomide chemotherapy and radiotherapy). 6. karnofsky functional status rating \> or equal to 70. 7. adequate bone marrow function including the absence of lymphopenia (anc \> 1,500/ mm3; hemoglobin \> 10g/dl ; platelet count \>100,000/mm3), adequate liver function (serum glutamic oxaloacetic transaminase/ aspartate aminotransferase \[ast\], alanine amino transferase \[alt\] \<2.5 times institutional upper limit of normals \[iulns\] ), and adequate renal function (bun and creatinine \<1.5 times iulns) 8. agree to surgical indications of heart \& lung and without the coagulation system disease 9. except for surgery and radiotherapy and chemotherapy before vaccine treatment, no other cancer treatment is received. exclusion criteria: 1. inability to comply with study-related procedures 2. unavailability of at least 6 doses of vaccine 3. severe allergies 4. unstable or severe intercurrent medical conditions 5. current diagnosis of human immunodeficiency virus and patients with active uncontrolled infection. 6. patients with any systemic disease needed to be treated with immunosuppressant or corticosteroids. 7. any other clinical trials within 30 days pre-vaccination. 8. female patients who are pregnant or breastfeeding 9. carmustine extended release implant surgery within 6 months 10. steroidal drugs are currently being used systemically.

Keywords: supratentorial glioma
an extention study of safety of canakinumab in japanese patients with periodic fever syndromes

Conditions: Periodic Fevers Syndrome

Summary: the primary objective of this study was to evaluate safety and tolerability of acz885 in this extension study. this extension study offered the opportunity for participants who completed epoch 4 of the preceding cacz885n2301 (nct02059291) study to continue to be treated with acz885 until approval in japan of the drug in periodic fever syndromes or until development of acz885 in periodic fever syndromes was suspended.


Eligibility criteria:
inclusion criteria: * completed epoch 4 of the cacz885n2301 study in japan before the approval of canakinumab in japan * written informed consent. parent or legal guardian's written informed consent and child's assent, if appropriate, are required before any assessment is performed for patients \< 20 years of age exclusion criteria: * any conditions or significant medical problems in which the investigator judges the patient should not enter this extension study

Keywords: canakinumab, interleukin-1 periodic fevers syndrome traps hids crfmf auto-inflammatory diseases extension study
model-driven individualized transcranial direct current stimulation for the treatment of insomnia disorders

Conditions: Insomnia

Summary: this study is designed to evaluate the efficacy and to explore the best individualized stimulus paradigm of transcranial electrical stimulation for insomnia patients.

this study employs a randomized double-blind placebo-controlled design, with blinding applied to both the assessors and patients, while the therapists remain unblinded. a total of 40 patients with insomnia disorders meeting the inclusion criteria were recruited from the shanghai mental health center and randomly assigned to either the tdcs active stimulation group or the tdcs sham stimulation group, with 20 patients in each group. all patients underwent clinical assessments, magnetic resonance imaging (mri) scans, and high-density electroencephalogram (eeg) parameter collections at baseline. based on the mri structural images and high-density eeg parameters, individualized modeling was conducted to determine specific stimulation parameter schemes (stimulation sites, stimulation intensity, and electrode placement methods). detailed modeling methods and selection of stimulation parameters can be found in the intervention methods section. stimulation was carried out for a total of 2 weeks, with one session per day on weekdays, totaling 10 sessions, each lasting thirty minutes.

Eligibility criteria:
inclusion criteria: 1. age between 18 and 65 years; 2. meets the diagnostic criteria for insomnia disorder according to the diagnostic and statistical manual of mental disorders, fifth edition (dsm-5) 3. has not taken psychiatric medications in the 8 weeks prior to enrollment or has been on stable psychiatric medication for 8 weeks (excluding benzodiazepines); 4. insomnia severity as indicated by an isi score \> 10; 5. minimum education level of junior high school or above. exclusion criteria: 1. past or current diagnosis of disorders other than insomnia disorder, anxiety disorder, or depressive disorder according to dsm-5; 2. currently using benzodiazepines as sleep aids; 3. moderate to severe anxiety or depression (hamd-17 score \> 16 or hama score \> 24); 4. patients with obstructive sleep apnea syndrome; 5. previous treatment with ect, rtms, tes, or cognitive behavioral therapy for insomnia disorder; 6. severe physical illnesses or any condition that may induce seizures or intracranial hypertension, including cardiovascular or respiratory diseases; 7. history of neurological disorders (e.g., epilepsy, cerebrovascular accidents) or history of brain injury or brain surgery; 8. presence of implantable medical devices such as intracranial stents, cardiac pacemakers, coronary stents, or cochlear implants; 9. severe negative thoughts or high suicide risk; 10. pregnant or planning to conceive in the near future.

Keywords: insomnia transcranial direct current stimulation
mortality among children with congenital heart defects in norway

Conditions: Congenital Heart Disease

Summary: to describe mortality among children with congenital heart defects in norway


Eligibility criteria:
inclusion criteria: * children with congenital heart defects exclusion criteria: * no
effect of smartphone overuse on hand strength and function in physical therapy students

Conditions: Smartphone Addiction

Summary: the present study aimed to measure wrist flexor and extensor muscle strength, hand grip strength, wrist pain and function in smartphone addicts and non-addicts

smartphones have become ubiquitous worldwide, offering significant potential for medical applications by providing healthcare professionals and students with instant access to resources for informed decision-making. however, despite their benefits, overuse of smartphones can lead to physical health issues. grip strength is recognized as an indicator of overall muscle strength, upper limb function, and various health conditions. isokinetic testing, a reliable method for measuring muscle performance, has been widely used in studying low back pain but less commonly applied to wrist strength assessment. currently, there is a lack of evidence regarding the impact of smartphone overuse on wrist flexor and extensor peak torque, handgrip strength, and function. this research aims to investigate these aspects, providing insights into upper extremity function and potentially aiding ergonomists in addressing musculoskeletal disorders. the study's findings could contribute to the biomechanical evaluation and design of upper extremity tasks, enhance understanding of wrist functioning, and inform ergonomic design considerations. additionally, the results may help smartphone users adopt better postures and grasping techniques to minimize injuries and maintain hand function, ultimately improving their quality of life.

Eligibility criteria:
inclusion criteria: * age of subjects 18 to 25 years. * body mass index from 18, but less than 25 kg/m2. * experimental group, healthy subjects who are smartphone users for at least two years prior to study. exclusion criteria: * subjects with a history of neurological disorder affecting the upper extremities, vestibular dysfunction, or balance disorder. * deformities of elbow or hand. * any recent upper limb fracture or trauma. * disorders like carpal tunnel syndrome, radiculopathy or tendinopathy. * individuals going to the gym or athletes. * individuals who smoke. * subjects who had cognitive, linguistic or vision impairment which limited their use of instruments and questionnaire.
does the embryo transfer technique affect the success of in vitro fertilization?

Conditions: Infertility; Assisted Reproductive Technology; IVF

Summary: prospective, open, randomized, parallel, two-arm trial to compare the clinical pregnancy rate between most commonly used two embryo transfer techniques: trial followed by transfer technique and afterloading technique

eligible patients will be informed about the possibility of participating in the clinical trial in the beginning of treatment and on the day et, a signed consent form will be collected from those recipients who confirmed their participation. these patients will be randomized immediately before the et procedure by sequentially numbered, opaque, sealed envelopes

Eligibility criteria:
inclusion criteria: 1. patient has given written informed consent 2. bmi 18-30 kg/m2 3. \< 2 previous failed ivf trials 4. at least two good quality embryos on the day of transfer exclusion criteria: 1. congenital uterine anomaly 2. untreated endometrial polyp or fibroid distorting uterine cavity 3. presence of hydrosalpinx 4.2 or more prior ivf trial failure 5.moderate to severe endometriosis 6.recurrent pregnancy loss history
an efficacy and safety study of epoetin alfa for initiation and maintenance treatment of patients with anemia associated with chronic kidney disease

Conditions: Anemia

Summary: the purpose of this study is to demonstrate that once weekly and once every-2-weeks treatment with epoetin alfa, in patients with anemia associated with chronic kidney disease, is not less effective than the approved treatment with epoetin alfa that is given 3 times weekly with respect to changes in hemoglobin.

this is a open-label (all people know the identity of the intervention), randomized (the study medication is assigned by chance), multicenter study designed to show that 2 alternative dosing regimens, once weekly and once every-2-weeks (given at doses equivalent to 50 iu/kg 3 times a week) are not inferior to the 3-times-weekly dosing regimen. approximately 375 patients with anemia will be enrolled in this study. patients will be randomly assigned to receive epoetin alfa by subcutaneous (sc) injection according to one of the following 3 regimens: 3 times weekly (group 1), once weekly (group 2), or once every 2 weeks (group 3) for 22 weeks. thereafter, patients in group 1 will be switched to the once-weekly dosing regimen for an additional 22 weeks, and patients in groups 2 and 3 will continue their current treatment for an additional 22 weeks. the total duration of the open-label treatment phase is 44 weeks which will include initiation and maintenance treatment periods (with the goal of increasing, then maintaining, the hemoglobin level between 11.0 and 11.9 g/dl inclusive) and a safety period (to assess longer exposure to epoetin alfa treatment and any period of hemoglobin instability during the transition from 3-times-weekly to once-weekly dosing). starting doses of epoetin alfa in the 3-times-weekly, once-weekly, and every-2-weeks groups will be 50 iu/kg, 10,000 iu, and 20,000 iu, respectively; thereafter adjusted according to weekly hemoglobin concentrations. safety evaluations will include assessment of adverse events, laboratory tests, physical examinations, and vital signs.

Eligibility criteria:
inclusion criteria: * meet the diagnostic criteria for chronic kidney disease, defined as a glomerular filtration rate (gfr) more than or equal to 15 ml/min per 1.73 m2 and less than 60 ml/min per 1.73 m2 (stages 3 and 4) as calculated by the central laboratory * require support of an erythropoietin receptor agonist exclusion criteria: * uncontrolled hypertension * serum ferritin level less than 50 ng/ml * serum iron overload * severe congestive heart failure * active infection

Keywords: anemia chronic kidney disease kidney disease epoetin alfa procrit
longitudinal study of neighborhood predictors of cvd

Conditions: Cardiovascular Diseases; Heart Diseases

Summary: to examine how neighborhood-level factors interact with individual characteristics to predict incidence of cardiovascular disease and all-cause mortality.

background: there are few comprehensive databases that allow for a longitudinal examination of how neighborhood-level factors may interact with individual characteristics to predict incident cases of cardiovascular disease (cvd) and all-cause mortality. this cross-institutional project joins investigators from karolinska institutet in sweden and stanford university, known for their expertise in immigrant health and social inequalities in cvd. design narrative: the study examines how neighborhood social characteristics (e.g., neighborhood socioeconomic status (ses), social disintegration, socioeconomic and ethnic segregation, social capital), physical environments (e.g., geocoded assets including goods and services contributing to health such as educational and recreational resources; barriers to health including pollution, industries, waste dumps, criminal activity, alcohol and fast food outlets) and individual factors (e.g., ses, cardiovascular disease {cvd} risk factors, country of birth and social networks) may interrelate to predict cvd \[morbidity and mortality\] and all-cause mortality. data will be used from a newly created, comprehensive set of swedish databases, migmed and migsalls. migmed (1990-2002) includes data for the entire swedish population of 6 million women and men aged 25 and older, of whom 600,000 are first generation immigrants. their addresses have been geocoded, yielding 9,677 neighborhoods, which will be reduced to a smaller number of defined units by cluster analyses. migmed includes an annual assessment of individual-level sociodemographic and health indicators. data will also be analyzed from migsalls (1988-2002), which includes more in-depth data from face-to-face interviews with a representative sample of approximately 18,000 women and men aged 25-74, of whom 2,000 are first generation immigrants. migsalls contains similar individual- and neighborhood-level factors as migmed, as well as extensive information on factors that may mediate relationships between neighborhoods and cvd outcomes (e.g., cvd risk factors such as smoking, weight, physical activity, and blood pressure). information from these two datasets will be matched to hospital and death records (300,000 deaths and 140,000 incidence cases of cvd expected between 1988-2002), thus creating one of the largest databases in the world involving men and women from diverse ses levels and countries of origin.

Eligibility criteria:
no eligibility criteria